A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Advanced Solid Tumor · Metastatic Solid Tumor · Non-small Cell Lung Cancer (NSCLC) · Head and Neck (HNSCC) · Pancreatic Cancer · Renal Cell Carcinoma (RCC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yonsei University Health System, Severance Hospital, Seoul, South Korea
Asan Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea